SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Wockhardt declines on recalling 109,744 bottles of a high blood pressure drug

15 May 2014 Evaluate

Wockhardt is currently trading at Rs. 785.70, down by 9.55 points or 1.20% from its previous closing of Rs. 795.25 on the BSE.

The scrip opened at Rs. 802.85 and has touched a high and low of Rs. 819.90 and Rs. 778.50 respectively. So far 276207 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 1909.85 on 16-May-2013 and a 52 week low of Rs. 336.60 on 16-Dec-2013.

Last one week high and low of the scrip stood at Rs. 822.00 and Rs. 748.50 respectively. The current market cap of the company is Rs. 8768.66 crore.

The promoters holding in the company stood at 74.70% while Institutions and Non-Institutions held 7.84% and 17.32% respectively.

Wockhardt has reportedly recalled 109,744 bottles of a high blood pressure drug -- metoprolol succinate -- in the United States after it failed a dissolution test. Metoprolol succinate extended release is a cheaper generic form of AstraZeneca Plc’s branded drug Toprol.

Dissolution tests are commonly conducted to check the time taken for the active ingredient in a drug to release into the body, and help predict how the drug performs inside the body.

Last year, two of the company’s manufacturing plants were banned from exporting to the United States after the FDA found violations of manufacturing standards that the agency believed could compromise the quality of drugs. One of those plants was making metoprolol succinate for the United States.

Wockhardt Share Price

1396.80 37.70 (2.77%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×